undamentalytics Newsletter
Sign in

Regenxbio Inc. cash flow statement

In fiscal 2025, Regenxbio Inc.'s operations generated −$124m of cash; it spent $2.4m on capital projects, leaving free cash flow of −$126m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash from operations−3−2−23−49−58105−108−54219−207−218−173−124−247
Depreciation and amortisation00013478101317161615
Stock-based pay—03711172732394140383535
Capital spending——187131227843110223
Free cash flow——−23−57−6591−119−81135−238−228−176−126−250
Free cash flow after stock pay——−26−64−7675−146−11396−279−269−214−161−285
Shares issued————82190————————

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: NUVB vs RGNXABUS vs RGNXIBRX vs RGNX

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Regenxbio Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Regenxbio Inc.